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Background
CMR based pattern of late enhancement (LE) has been
shown to differentiate between Fabry's disease, and hyper-
trophic cardiomyopathy. In Fabry's disease, LE is found at
the lateral wall, while it is located at the septal insertion
points of the right ventricle in hypertrophic cardiomyop-
athy. However, given that both conditions result in
increased wall thickness, and in some patients, there is
generalized LE, differentiation between the two cardiomy-
opathies becomes difficult. The value of CMR-based
inflammatory markers such as edema (T2), and hypere-
mia (EE), as tools to further distinguish between these car-
diomyopathies is not understood.
Methods
We assessed 12 patients with Fabry's disease (5 males, 42
± 18 years) and 8 patients with hypertrophic cardiomyop-
athy (4 males, 62 ± 18 years) using a 1.5 T MRI system
(Avanto®, Siemens Medical Solutions, Erlangen, Ger-
many). Left ventricular (LV) function and volumes were
assessed using standard methods. Myocardial edema was
imaged with a T2-weighted STIR sequence. Early contrast
enhancement was quantified in free-breathing T1-
weighted spin echo images before and early (over 4 min-
utes) after administration of 0.1 mmol/kg Gd-DTPA. Irre-
versible injury was visually assessed in images obtained by
an inversion-recovery prepared gradient echo sequence 10
minutes after a total of 0.2 mmol/kg Gd-DTPA.
Results
All patients had evidence of myocardial fibrosis. Measures
of EE differed significantly between the two groups
(Fabry's disease 6.85 ± 2.96; HCM 3.64 ± 0.97; p < 0.05).
In contrast, there was no significant difference between T2
ratios (1.56 ± 0.24 vs. 1.72 ± 0.36, p = ns), LVEDV (133 ±
37 ml vs. 141 ± 43 ml, p = ns), LVESV (51 ± 18 ml vs. 49
± 31 ml, p = ns), LVSV (82 ± 21 ml vs. 91 ± 17 ml, p = ns),
nor LVEF (62 ± 4% vs. 67 ± 10%, p = ns). Figure 1.
Conclusion
Early contrast enhancement is increased in Fabry's disease
and may help to differentiate this disease from other
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Elevated early enhancement ration in a patient with Fabry's 
disease (upper panel) 4.68, compared to a ration of 2.24 in a 
patient with hypertrophic cardiomyopathy (lower panel).Page 1 of 2
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causes of LV hypertrophy such as hypertrophic cardiomy-
opathy. Therefore, in addition to LE, EE should be per-
formed in patients with hypertrophy of uncertain
etiology.Page 2 of 2
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